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OBJECTIVES: Celiac disease (CD) is a chronic enteropathy characterized by an autoimmune reaction in the small
intestine of genetically susceptible individuals. The underlying causes of autoimmune reaction and its
effect on host metabolism remain largely unknown. Herein, we apply lipidomics to elucidate the early
events preceding clinical CD in a cohort of Finnish children, followed up in the Type 1 Diabetes
Prediction and Prevention study.
METHODS: Mass spectrometry–based lipidomics profiling was applied to a longitudinal/prospective series of 233
plasma samples obtained from CD progressors (n 5 23) and healthy controls (n 5 23), matched for
human leukocyte antigen (HLA) risk, sex, and age. The children were followed from birth until diagnosis
of clinical CD and subsequent introduction of a gluten-free diet.
RESULTS: Twenty-three children progressed to CD at a mean age of 4.8 years. They showed increased amounts of
triacylglycerols (TGs) of low carbon number and double bond count and a decreased level of
phosphatidylcholinesbyage3monthsascompared tocontrols. Thesedifferenceswereexacerbatedwithage
but were not observed at birth (cord blood). No significant differences were observed in the essential TGs.
DISCUSSION: Our preliminary findings suggest that abnormal lipid metabolism associates with the development of
clinical CD and occurs already before the first introduction of gluten to the diet. Moreover, our data
suggest that the specific TGs found elevated in CD progressors may be due to a host response to
compromised intake of essential lipids in the small intestine, requiring de novo lipogenesis.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A44
Clinical and Translational Gastroenterology 2019;10:e-00044. https://doi.org/10.14309/ctg.0000000000000044
INTRODUCTION
Celiac disease (CD) is a chronic, systemic, autoimmune enter-
opathy triggered by dietary gluten and related prolamins from rye
and barley in genetically susceptible individuals (1). Approxi-
mately 90%–95% of patients with CD express human leukocyte
antigen (HLA)-DQ2 protein, whereas the remaining (5%–10%)
express HLA-DQ8 (2). CD is characterized by a wide range of
gastrointestinal and extraintestinal symptoms that include
diarrhea, weight loss, abdominal distention, malabsorption,
and iron deﬁciency anemia (1). Serologic tests such as mea-
surement of serum immunoglobulin A (IgA) and/or immu-
noglobulin G (IgG) tissue transglutaminase antibodies, IgA
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endomysial antibodies, and deamidated gliadin peptide anti-
bodies (IgG class) are performed for screening and diagnosis of
CD. In addition, a biopsy of small intestine is still required in
many countries to conﬁrm the diagnosis (3).
The incidence of CD and other autoimmune diseases such as
type 1 diabetes (T1D) has been increasing in children and adults
over the past decades (4,5). The occurrence of these autoimmune
diseases is higher in the Nordic countries (6) than elsewhere, with
the highest prevalence of CD occurring in Sweden (29/1,000 by
age 12 years) and the highest incidence rate of T1D occurring in
Finland (64/100,000/year for children younger than 15 years)
(7,8). Approximately 10% of patients with T1D develop overt CD
(9). On the other hand, people with CD are at risk of T1D before
age 20 years (10). These autoimmune diseases share common,
predisposing alleles in the class II HLA-region as the DR3-DQ2
and DR4-DQ8 haplotypes (11).
Recent studies show that in addition to genetic predisposition
and exposure to dietary gluten, other factors such as the composi-
tion of the intestinalmicrobiota, birth deliverymode, infant feeding,
and the use of antibioticsmay also aﬀect the onset of CD (12). Thus,
the early pathogenesis of CD is still poorly understood, and the
identiﬁcationofmolecular signatures associatedwithprogression to
overt CD remains an unmet medical need (13). The health burden
ofCD in termsof quality of life, complications,mortality, and cost of
treatment is considerable, meaning that its prevention has become,
in the last decade, an important area of research.
Metabolomics is the study of small (,1,500Da)molecules and
their functions in cells, tissues, and body ﬂuids (14).Metabolomic
studies in adults diagnosed with active CD (15) identiﬁedmarked
changes in serum and urine metabolic proﬁles, along with altered
intestinal microbiota (16–18). Interestingly, a recent, small pro-
spective study suggests an altered early trajectory of the gut
microbiome (ages 4 and 6 months) in children who later pro-
gressed to CD (19).
Lipids are a structurally and functionally highly diverse groupof
metabolites withmany important biological functions including as
components of cell membranes, intermediates in signaling path-
ways, and as energy sources. The emergence of lipidomics, a dis-
cipline closely related to metabolomics, has enabled researchers to
study lipidomes and lipid metabolism at the systems level (20,21).
Because of their diverse roles in biological systems, it is not sur-
prising that lipid-related disturbances occur in many common
diseases. In our previous lipidomics studies, for example, we found
that dysregulated lipid metabolism precedes islet autoimmunity
and overt disease in children who later progressed to T1D (22,23).
Here, we applied a lipidomics approach, in a longitudinal
study setting, with the aim of elucidating the early events pre-
ceding onset of overt CD.
METHODS
Study design and protocol
The children included in the present study are from the Type 1
Diabetes Prediction and Prevention (DIPP) cohort, which is an
ongoing prospective study initiated in 1994. In the DIPP study,
parents of newborn infants at the University Hospitals of Turku,
Tampere, and Oulu in Finland are asked for permission to screen
the child for HLA alleles conferring the risk of T1D, using um-
bilical cord blood. Families of children identiﬁed as having an
increasedHLA-conferred risk of T1Dare invited to join the study.
Our analysis included children born at Tampere University
Hospital between August 1999 and September 2005. During that
period, 23,839 childrenwere screened at birth for increased risk of
T1D, and 2,642 eligible children were enrolled in the follow-up
andhad at least 2 visits to the study clinic. These children carry the
high-risk HLA DQB1*02/*03:02 genotype or the moderate-risk
HLA-DQB1*03:02/x genotype (x  DQB1*02, 03:01, or 06:02).
More than 1,200 of these children took part in the DIPP-CD
study. The DIPP study in Tampere followed the children at reg-
ular intervals at the ages of 3, 6, 12, 18, and 24 months and
subsequently at intervals of 12months for children without T1D-
related autoantibodies. At each visit, the families were inter-
viewed for diet, infections, growth, and important family-related
issues, and the children gave a nonfasting venous blood sample.
The children were followed for 4 CD-related antibodies, anti-
tissue transglutaminase (anti-tTG), anti-endomysium, anti-
gliadin (AgA-IgG and AgA-IgA), and anti-reticulin antibodies,
and for T1D-associated autoantibodies, islet cell antibody. If
a sample was positive for islet cell antibody, insulin autoantibody,
antibodies against tyrosine phosphatase-like protein (IA-2A),
and glutamate decarboxylase were measured from all samples
taken from that child. From the beginning of 2003, all samples
were measured for the 4 T1D-associated autoantibodies.
All children participating in this study were of white origin.
They were initially identiﬁed based on positivity for IgG class
tissue transglutaminase antibodies. As a consequence, IgA-
deﬁcient subjects were excluded. One of the mothers had CD.
Furthermore, the children in the CD follow-up cohort were an-
nually screened for anti-tTG antibodies (tTGAs) using a com-
mercial kit (Celikey Pharmacia Diagnostics, Freiburg, Germany).
If any given child’s sample was found to be positive for tTGA, all
of that child’s previous and following samples were analyzed for
the entire set of CD-related antibodies. A duodenal biopsy was
recommended for all tTGA-positive children. If the biopsy was
consistent with the ESPGHAN criteria of 1990, a gluten-free diet
(GFD) was recommended. Three of the CD cases were also di-
agnosed with T1D, one just before the diagnosis of CD and the
other ones after the diagnoses of CD (62 and 76 months later).
We randomly selected 23 children (12 males and 11 females)
with biopsy-proven CD (progressors) and a control for each
progressor matched for age, sex, and with the same risk HLA
alleles, and living in the Tampere region throughout the whole
follow-up period. None of the controls were diagnosed with T1D.
The original HLA screening for patients with CD and suitable
controls was also completed to a “full-house”DQ typing to verify
the presence of DQA1*05 in selected DQB1*02-positive children
(24). These clinical and genetic annotations of the participants are
given in Table 1. Furthermore, the children were exclusively
breastfed until 1.6 months (median), and some were exclusively
breastfed up to age 8.0months. The ﬁrst exposure to gluten in this
study was at a median age of 6.0 months. The children (case and
control) had comparable (nominal and nonsigniﬁcant diﬀerence)
energy (kJ), fat (g), carbohydrate (oat, rye, and wheat), and gluten
intakes (see Figures S1 and S2, Supplementary Digital Content 1,
http://links.lww.com/CTG/A44).
Maternal total diet during pregnancy and lactation was
ascertained by a validated food frequency questionnaire (25).
Infant feeding was studied by structured questionnaires, which
families ﬁlled in at home, and which were checked during the
clinic visits. The child’s diet was assessed with 3-day food records
at 3, 6, and 12months, followed by 2, 3, 4, and 6 years of age visits.
The food records were posted before the study visit or given at the
previous visit with detailed, written instructions. The families and
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daycare personnel were instructed to write down all the foods,
drinks, and dietary supplements the child consumed, with the
amounts and brand names during 1weekend day and 2weekdays.
The study nurses checked the records at the study visit and helped
to estimate any incomplete portion sizes with a picture booklet.
The collection, processing, and calculation of food consumption
data have been described previously in detail (26). Themothers of
CD progressors and controls had comparable body mass indexes
and energy, fat, and carbohydrate intakes during pregnancy and
lactation (see Figures S3 and S4, Supplementary Digital Content 1,
http://links.lww.com/CTG/A44).
Altogether, 121 plasma samples from children developing CD
and 112 plasma samples from matched, healthy controls were
analyzed, averaging more than 5 prospective follow-up samples
for each child. Log-transformed intensities of the lipid meas-
urements from these are given in Figures S5 and S6 (Supple-
mentary Digital Content 1, http://links.lww.com/CTG/A44).
Analysis of molecular lipids
A total of 233 plasma samples were randomized and extracted
using a modiﬁed version of the Folch procedure, similar to
a protocol described recently (27). Promptly after extraction,
10 mL of 0.9% NaCl and 120 mL of CHCl3:MeOH (2:1, v/v)
containing 2.5 mg·mL21 internal standard solution (for quality
control and normalization purposes) were added to 10mL of each
plasma sample. A detailed protocol of plasma lipid proﬁling and
data preprocessing is given in Supplementary Notes (see Sup-
plementary Digital Content 1, http://links.lww.com/CTG/A44).
Statistical methods
The samples fromCD progressors and controls were divided into
diﬀerent age groups based on time diﬀerence between the date of
the sample withdrawn and date of birth of the subject (see Figure
S7, SupplementaryDigital Content 1, http://links.lww.com/CTG/
A44). If more than 2 samples from the same case matched a time
interval, the closest was taken. The data were then log2 trans-
formed. Homogeneity of the samples was assessed by principal
component analysis (28), and no outliers were detected.
R software (http://www.r-project.org) was used for data
analysis and visualization. Principal component analysis was
performed using “prcomp()” function included in the “stats”
package. The eﬀect of diﬀerent factors such as age, sex, and
condition (healthy or CD) on the lipidomics data set was evalu-
ated. The data were centered to zero mean and unit variance. The
relative contribution of each factor to the total variance in the data
set was estimated by ﬁtting a linear regression model, where the
normalized intensities of metabolites were regressed to the factor
of interest, and thereby, median marginal coeﬃcients (R2) were
estimated. This analysis was performed using “scater” package
(see Figure S8, SupplementaryDigital Content 1, http://links.lww.
com/CTG/A44). Partial least squares discriminant analysis
(PLS-DA) (29) and variable importance in projection (VIP) scores
(30) were estimated by an array of functions coded in “ropls”
package. Moreover, the PLS-DA models were cross-validated (31)
by 7-fold cross-validation as implemented in “ropls” package, and
Q2 (an estimate of model’s predictability) and R2 were obtained.
The longitudinal proﬁles of the lipids in the samples obtained
from CD progressors and matched healthy controls were com-
pared using linear mixed-eﬀects (LMEs) models (32) as imple-
mented in the “lme()” function of “nlme” package. The intensity of
ametabolite (yˆ) in a sample (j) is a function ofmultiple factors such
as follow-up age, sex, case/control, and subject-wise variability. The
clinical and genetic factors of the children were matched and
standardized in this study (Table 1); other factors such as subject-
wise variability can be modeled and derived using LME models.
The LME models were restricted to constant terms with the ﬁxed
eﬀect being CD progression/nonprogression (control), age, sex,
and the random eﬀect being subject-wise variation in comparison
to the group-speciﬁc mean level. Fitted LME models showed that
sex diﬀerence has nominal eﬀect on the metabolite intensities. The
fully parametrized model was compared with a null model using
analysis of variance (ANOVA) (33) (“aov()” as deployed in the
“stats” package). The lipid proﬁles that changed signiﬁcantly (P,
0.05)were subjected to false discovery rate (FDR) adjustment using
p-adjust(). Lipid proﬁles with FDR,0.05 were listed.
Next, post hoc analysis using the Tukey test for honest sig-
niﬁcant diﬀerence (HSD) was performed on these selected lipids
to see, if at all, they are changing between progressors and non-
progressors at a particular age. A list of diﬀerentially altered lipids
that also showed HSD (P values, 0.05) between CD progressors
and healthy controls at a particular age was marked. These lipids
were considered for further analysis.
HSD was performed using “TukeyHSD()” function deployed
in the “stats” package. Loess regression was performed using
“loess()” deployed in the “stats” package. The Spearman
Table 1. Demographic and clinical characteristics of the study
subjects
Celiac
disease
Healthy
controls
No. of subjects 23 23
Sex
Male 12 12
Female 11 11
HLA DR-DQ genotype
(DR3)-DQA1*05-DQB1*02/
DRB1*04-DQA1*03-DQB1*0302
17 17
DRB1*04-DQA1*03-DQB1*0302/x
 DQB1*02, 03:01, or 06:02
6 6
Duration of exclusive breastfeeding
(median)
1.4 mo 1.6 mo
Duration of breastfeeding (median) 8.0 mo 8.0 mo
Age at first gluten intake (median) 6.0 mo 5.5 mo
Age at first tTGA positivity (median)
(seroconversion)
58 mo —
First tTGA level in plasma (median
endotoxininduced uveitis (EIU))
116.8 —
Age at endoscopy (median) 58.5 mo —
tTGA level after GFD (median
endotoxininduced uveitis (EIU))
7.1 —
Total follow-up age from birth (median) 6.1 yr 6.2 yr
Plasma samples analyzed by lipidomics 121 112
EIU, endotoxininduced uveitis; GFD, gluten-free diet; tTGA, tissue
transglutaminase antibody.
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correlation coeﬃcient was calculated using “rcorr()” function
implemented in “Hmisc” package. “Heatmap.2()” and “box-
plot()” were used for data visualization.
RESULTS
Global plasma lipidome in progression to CD
The complete lipidomics data set was ﬁrst explored using
multivariate analysis. Among other factors aﬀecting the lip-
idome, age was found to be a major confounding factor (see
Figure S8, Supplementary Digital Content 1, http://links.lww.
com/CTG/A44). PLS-DA (29) of lipidomics data from all 233
longitudinal samples suggested that children who later pro-
gressed to CD (progressors) may have diﬀerent lipid proﬁles in
comparison to their matched healthy controls (Figure 1a).
Diﬀerent classes of lipids such as cholesterol esters (CEs),
phosphatidylcholines (PCs), lysophosphatidylcholines, phos-
phatidylethanolamines, phosphatidylinositols, sphingomyelins
(SMs), and triacylglycerols (TGs) were aﬀected (regression co-
eﬃcient [60.05] and VIP scores (30) .1) (Figure 1b).
Diﬀerences between cases and controls were observed already by
age 3 months, for example, before the introduction of gluten to the
diet (Figure 1c). TGs, PCs, and CEs weremostly aﬀected (regression
coeﬃcient [60.05] and VIP (30) scores.1) at this age (Figure 1d).
The cord plasma lipidome clustered distinctly fromother age groups
(see Figure S9, Supplementary Digital Content 1, http://links.lww.
com/CTG/A44). However, no signiﬁcant diﬀerences (HSD,P values
. 0.05) in the cord plasma lipids were observed between CD pro-
gressors and their matched healthy controls (Figure 2a).
Molecular lipids in progression to overt CD
Longitudinal analysis of lipidomic proﬁles at the individual lipid
level identiﬁed 80molecular lipids (from a total of 239) occurring
at signiﬁcantly diﬀerent levels over time between CD progressors
and healthy controls (FDR-adjusted P values, 0.05) (Figure 2a).
Figure 1. Classification of CD and healthy controls, based on their lipidome. (a) PLS-DA score plot showing difference in the lipidome between CD
progressors (cyan) and healthy controls (magenta). (b) A regression plot of the lipids and their VIP scores obtained from the PLS-DAmodel. The lipids are
grouped and color coded by their classes. (c) PLS-DA score plot showing difference in the lipidome in CD progressors along the age. (d) A regression plot of
the lipids and their VIP scores at age 3 months. The lipids are grouped and color coded by their classes. CD, celiac disease; PLS-DA, partial least squares
discriminant analysis; VIP, variable importance in projection.
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The level and direction of regulation of TGs depend on their
chemical structure. There was an association between the fold
change in TGs (CD progressors vs healthy controls) and the TG
double bond count as well as the TGcarbonnumber (Figure 2b–e).
At age 3months, TGswith lowerdouble bond andcarbonnumbers
were found to have increased in CD progressors as compared to
matched,healthy controls,with coeﬃcients (R520.13;Pvalues5
0.19) and (R520.54; P values5 0.0001), respectively, for double
bond count and carbon number (Figure 2b, d). Interestingly, at
a later age, these TGs with lower double bond and carbon numbers
were downregulated with (R 5 0.79; P values 5 0.08) and (R 5
0.44;P values5 0.0002), respectively (Figure 2c, e). Notably, 4 such
TGs were elevated in progressors at age 3 months (HSD, P values
, 0.05).No signiﬁcant changeswere detected for dietaryTGs, such
as those containing polyunsaturated fatty acids. Representative
longitudinal proﬁles for selected signiﬁcantly altered lipidsbetween
CD progressors and healthy controls are shown in Figure 3.
Impact of tissue transglutaminase antibodies on
lipidomic profiles
Tissue transglutaminase (tTG) is a multifunctional, calcium-
dependent enzyme (Enzyme Commission number [EC] 2.3.2.13)
that plays an important role in the pathogenesis of CD. Anti-
bodies produced against tTG, anti-tissue transglutaminase
antibodies (tTGA), are used as serological markers with high
sensitivity (99%) and reasonable speciﬁcity (.90%) for the di-
agnosis of CD (34–36).
We examined tTGA titers in 23 CD progressors at 2 diﬀerent
stages: (i) immediately after the seroconversion for tTGA and
(ii) 6–12 months after both seroconversion and introduction of
GFD. First, we identiﬁed at least 7 “essential” TGs, i.e., TGs of
dietaryorigin, in our lipidomics data set. The identities of theseTGs
were validated using external sources including both the Human
Metabolome Database (37) and FooDB.ca (http://foodb.ca/).
Spearman correlation analysis was then performed between the
levels of selected TGs (34 signiﬁcantly changed nonessential and 7
nonsigniﬁcantly changed essential TGs) and PCs (18 PCs 1 2
lysophosphatidylcholines) with measured tTGA levels at these
stages.Theaimwas todeterminewhether the systemic levels of TGs
and PCs are associated with antibody titers during CDprogression.
A positive correlation (Spearman rank coeﬃcient, davg510.174;
minimum P value 5 0.01) was found between the TG and tTGA
levels after seroconversion (Figure 4a). However, a negative cor-
relationwas found at a later age,where the levels of tTGAdecreased
considerably (davg 5 20.163; minimum P-value 5 0.05). In ad-
dition, at least 16 PCswere negatively correlated at these 2 diﬀerent
time points (davg5 20.02 and 20.13; minimum P values 5 0.01
and 0.02, respectively) (Figure 4b). It is known that GFD decreases
Figure 2. Number of acyl carbons in TGs. (a) Heatmap showing log2 FCs of significantly altered (FDR-adjusted P values, 0.05) longitudinal lipid profiles
between CD progressors and matched healthy controls, as identified by LME models. Here, blue and red depict downregulated and upregulated lipid
intensities in CD progressor as compared to their matched healthy controls, respectively, and white depicts no change. The lipids that changed specifically
(HSD,P values,0.05) at a particular age, as identified by the Tukey test forHSD, are highlightedwith a star “*”. (b and c) Correlation plots of log ratio or fold
changes of TGs and the number of acyl chain bonds incurred by them at early (3 months) and later ages (72 months), i.e., when gluten-free diet has been
started. R denotes ranked correlation coefficients. (d and e) Correlation plots of log ratio of TGs and the number of acyl chain carbon atoms in TGs at the
same age. The significantly changed (P, 0.05) TGs betweenCDprogressors and healthy controls (at any age) aremarked in dark pink. CD, celiac disease;
FC, fold change; FDR, false discovery rate; HSD, honest significant difference; LME, linear mixed effect; TG, triacylglycerol.
American College of Gastroenterology Clinical and Translational Gastroenterology
C
O
LO
N
Persistent Alterations in Plasma Lipid Profiles 5
tTGA levels in patients with CD (38), while it also improves the
total cholesterol levels and highdensity lipoprotein proﬁles without
any signiﬁcant increase in low density lipoproteins (39).
Impact of gluten on molecular lipids
We then divided the cohort into 3 subgroups: (i) before the in-
troduction of gluten in the diet (3 months), (ii) after the in-
troduction of gluten (12–36 months), and (iii) after the
introduction of GFD (72 months, CD progressors only).
We observed a decrease in the total essential TG level in the
plasma of the CD progressors after gluten intake (Figure 5a; see
Figure S10A, Supplementary Digital Content 1, http://links.
lww.com/CTG/A44). Introduction of GFD reversed this trend,
but the changes were not signiﬁcant (ANOVA, P values. 0.05)
(Figure 5a, e). On the other hand, levels of nonessential en-
dogenous TGs were decreased (ANOVA, P values 5 0.004) in
the plasma of theCDprogressors after commencement of gluten
intake and even after the diagnosis of clinical CD and in-
troduction of GFD (P values5 0.001). The trend in the change
of nonessential TGs was also observed in healthy controls
(P values5 0.007 and 0.01, respectively) (Figure 5b, e; see Figure
S10B, Supplementary Digital Content 1, http://links.lww.com/
CTG/A44). Moreover, there was a diﬀerence (P , 0.05) in
nonessential TGs levels between CD progressors and healthy
controls as predicted by the Tukey test for HSD (Figure 2a).
These ﬁndings suggest that dysregulation of lipid metabolism
might occur at an early stage of CD progression, even before the
introduction of gluten in the diet.
PCs were elevated both in the progressors (P , 0.004) and
controls (P, 0.007) after the commencement of gluten intake
(Figure 5c, e; see Figure S10C, Supplementary Digital Content
1, http://links.lww.com/CTG/A44). PCs are the major class of
phospholipids that form the cellular constituents required for
the assembly of biological membranes. In contrast to healthy
controls, no signiﬁcant diﬀerences in the SM level were ob-
served in the CD progressors after commencement of gluten
intake. A diﬀerence in the plasma SM level was observed only at
a later age after the introduction of GFD (Figure 5d, e; see
Figure S10D, Supplementary Digital Content 1, http://links.
lww.com/CTG/A44).
DISCUSSION
We identiﬁed systematic diﬀerences in plasma lipidomes between
children who progressed to clinical CD during the follow-up as
compared to children who remained healthy. These diﬀerences
were observed before the ﬁrst exposure to gluten in the diet and
before the ﬁrst signs of CD-associated autoimmunity. The dys-
regulation of plasma lipidome in CD progressors was dominated
by complex lipids such as PCs, TGs, and CEs. Because there is no
evidence of gut damage in any studies performed so far in indi-
vidualswho are autoantibody negative for tTGA, it is unlikely that
these systematic diﬀerences are caused by gluten from breast milk
or other sources in the infants’ diet causing damage to the gut
immediately after birth. An earlier lipidomics study in the Pre-
ventCD cohort did not ﬁnd signiﬁcant diﬀerences between CD
progressors andmatched controls at age 4months (40). However,
Figure 3. Longitudinal lipid profiles that are significantly different betweenCDprogressors and healthy controls. Lipid profiles in CD progressors aremarked
with black color and healthy controls with orange color, along with 95% confidence intervals, as shown by the area shaded around the curves. (a–f) shows
longitudinal profiles of CE(18:1), LPC(18:0), TG(47:0), SM(d32:1), PC(36:3), TG(18:2/18:2/18:2) or TG(18:3/18:2/18:1), respectively.
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that study used a targeted analysis focusing on a subset of phos-
pholipids and acyl-carnitines and did not measure TGs and CEs,
where the major changes were found to have occurred in our
study.
In this study, several nonessential TGs were upregulated in
CD progressors as early as age 3 months, i.e., before the ﬁrst
introduction of gluten to the diet. However, no signiﬁcant
changes in dietary TGs were found at this age. Lipid malab-
sorption is believed to be a side eﬀect of ﬂattened villi in the
small intestine (15,17). However, our data suggest that lipid-
related abnormalities are not caused by CD-related villous at-
rophy in the gut. One plausible explanation that arises is that
lipid malabsorption can lead to a reduction in cholesterol-
transporting lipoproteins and secretion of apolipoprotein-A1
(41,42). A decrease in the level of CEs in CD progressors during
the ﬁrst 3 months after birth supports this explanation.
Moreover, CEs were upregulated at a later age after the in-
troduction of GFD (Figures 2a and 3a). Lipid malabsorption
may thus occur at a very early age in CD progressors and,
therefore, de novo lipogenesis (43), as reﬂected by increased
levels of TGs with low carbon number and double bond con-
tent, may be necessarily increased to compensate for said
compromised lipid uptake. Interestingly, this phenomenon
was not observed at birth (i.e., in the cord blood data), thus
suggesting that the observed lipid dysregulation is not an in-
born phenomenon.
Furthermore, an inverse relationship between endogenous
TGs and tTGA titer after seroconversion and introduction of
GFD in the CD progressors also reaﬃrms the involvement of
TGs and other phospholipids (PCs) in CD progression. Indeed,
Figure 4. Correlation between plasma TGs and tTGA titers in CD progressors. (a) Heatmap showing the Spearman rank coefficient estimated between
significantly changedTG levels and tTGA titer in theplasmaof CDprogressors immediately after theSCand6–12months after theSCor introductionofGFD.
Red and blue depicts positive and negative correlations. (b) Heatmap showing the Spearman rank coefficient estimated between significantly changed PC
and plasma tTGA titer in CD progressors after SC and GFD. CD, celiac disease; GFD, gluten-free diet; PC, phosphatidylcholine; SC, seroconversion; TG,
triacylglycerol; tTGA, tissue transglutaminase antibody.
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there was an increase in cholesterol levels after the introduction
of GFD, and there was a decrease in tTGA titers, in agreement
with previous studies (38,39). Presumably, these lipids may play
a protective role against seroconversion to tTGA positivity and
CD progression.
We found, in earlier studies, that T1D is preceded by dys-
regulation of lipidmetabolism (22,44,45). The key ﬁndings from
these studies were that islet autoimmunity and overt T1D are
preceded by diminished phospholipid and TG levels. Although
there are some similarities at an early age in phospholipid
proﬁles in T1D and, as shown in the current study, CD pro-
gressors, no such similarities exist for TGs. The increase of TGs
with low carbon number and double bond count does seem to
be speciﬁc to CD progression. These TGs are associated, in
adults, with elevated liver fat in nonalcoholic fatty liver disease
(46,47), reﬂecting increased de novo lipogenesis and adipose
tissue lipolysis. In fact, patients with CD have, interestingly,
been found to be at an increased risk of nonalcoholic fatty liver
disease (48). Our ﬁndings may thus oﬀer an explanation for this
association.
The main limitation of this study is the relatively small
number of children included, and for that reason, our ﬁndings
should be considered preliminary and hypothesis generating.
However, the sample size is mitigated by the longitudinal study
setting, with 5 prospective samples, from birth until after the
introduction of GFD, on average, from each child. Moreover,
the subjects of our study were well matched with their controls
for genetic and environmental factors. In the current study, the
participants were initially screened for HLA-conferred sus-
ceptibility to T1D. There was an overrepresentation of DR3/
DR4-heterozygous (n5 17) and DR4-positive subjects (n5 6)
in the study series. In a general population, most CD cases are
DR3 positive. In our study, there were no signiﬁcant diﬀer-
ences in the lipidomic proﬁles between these 2 HLA groups.
Nevertheless, because of this selection bias, our ﬁndings may
not be translatable to other populations and thus need to
be conﬁrmed in a setting more representative of a general
population.
In summary, our study suggests that lipid-related abnormal-
ities in CD progressors demonstrably occur before the ﬁrst in-
troduction of gluten to the diet. These changes may be related to
impaired lipid absorption and de novo lipogenesis, with both of
these being part of the host response. Our preliminary ﬁndings
may have important clinical implications for the detection of
subjects at risk of CD and for the understanding of its early
pathogenesis.
Data accessibility
The lipidomics data sets and the clinical metadata generated in
this study have been submitted to MetaboLights (49) and can be
located using accession number (MTBLS729). The appropriate
Figure 5. Lipids that are significantly changed after gluten intake and by introduction of GFD. (a–d) Boxplots showing total log intensities of essential TGs,
nonessential TGs, PCs, and SMs in the CD progressors and healthy controls before (3 months) and after introduction of gluten (12–36 months) in the diet
and after introduction of GFD (72 months). (e) Grid map of P values obtained from ANOVA models by combining all possible conditions before/after the
gluten intake in CD progressors and healthy controls is given. The 3 different conditions are “BA-Glut”, before and after gluten; “AGlut-AGFD”, after gluten
and after gluten-free diet; and “BGlut-AGFD”, before gluten and after gluten-free diet. ANOVA, analysis of variance; CD, celiac disease; GFD, gluten-free
diet; PC, phosphatidylcholine; TG, triacylglycerol; SM, sphingomyelin.
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clinical metadata were linked to the lipidomics data set using the
ISA-creator package from MetaboLights.
Ethical approval and informed consent
The Ethics Committee of Tampere University Hospital approved
the study.Written informedconsentwas obtained fromtheparents
for HLA screening, autoantibody analysis, and intestinal biopsies.
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